Health Condition 1: G318- Other specified degenerative diseases of nervous system
Conditions
Interventions
Intervention1: Citicoline 500mg: 500mg twice daily
12 weeks
oral route
Control Intervention1: nil: nil
Sponsors
SRM medical college hospital and research centre
Eligibility
Inclusion criteria
Inclusion criteria: 1.Men and women aged 55-85 years, generally in good health, but exhibiting mild cognitive impairment, as indicated by a MoCA score of less than 26. 2. Patients having coexisting conditions like hypertension, diabetes mellitus, or hyperlipidemia. 3.Candidates must otherwise be in stable health, willing to give consent with no severe underlying medical issues that could interfere with participation
Exclusion criteria
Exclusion criteria: 1.Individuals with color blindness. 2.Those diagnosed with major medical or neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, intracranial haemorrhage, or localized brain lesions. 3.Women who are currently pregnant or planning pregnancy during the study. 4. Use of any medications that can impact cognitive function. 5.Presence of significant disorders involving the liver, kidneys, heart, lungs, or other critical organs. 6.Subjects who are heavy smokers, chronic alcohol users, or with a history of substance abuse. 7.Individuals with a known history of malignancy, HIV infection, cancer, AIDS, or other severe immunocompromised conditions. 8.Participants with severe cognitive impairment or advanced dementia. 9.Individuals who have been involved in any clinical trials using experimental drugs within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess then effect of citicoline during the study period in patients with mild cognitive impairment. Assess the change in Mo Ca score (baseline to visit 3) to assess if there is any improvement after taking the drug. Gradual Recovery from symptoms that the patient raised during initial visit.Timepoint: 6 month | — |
Secondary
| Measure | Time frame |
|---|---|
| To find out the adverse events during the study period caused by Citicoline. To evaluate treatment adherence/compliance by patients. Improvement in quality of life assessed by WHOQOL-BREF scale.Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr S Arunan
SRM medical college and hospital
Outcome results
None listed